

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61L 27/00, 15/28, C12N 5/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/18842</b> <b>(43) International Publication Date:</b> 29 May 1997 (29.05.97)
<b>(21) International Application Number:</b> PCT/EP96/05093 <b>(22) International Filing Date:</b> 19 November 1996 (19.11.96)  <b>(30) Priority Data:</b> PD95A000225      20 November 1995 (20.11.95)      IT  <b>(71) Applicant (for all designated States except US):</b> FIDIA ADVANCED BIOPOLYMERS S.R.L. [IT/IT]; Via De' Carpentieri, 3, I-72100 Brindisi (IT).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> ABATANGELO, Giovanni [IT/IT]; Via Pelosa, 32, I-35030 Saccolongo (IT). CALLEGARO, Lanfranco [IT/IT]; Via Monte Grappa, 6, I-35016 Thiene (IT).  <b>(74) Agent:</b> PASSINI, Angelo; Notarbartolo & Gervasi S.r.l., Corso di Porta Vittoria, 9, I-20122 Milan (IT).		<b>(81) Designated States:</b> AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> A BIOLOGIC MATERIAL COMPRISING AN EFFICIENT CULTURE OF BONE MARROW STEM CELLS PARTIALLY OR COMPLETELY DIFFERENTIATED INTO CONNECTIVE TISSUE CELLS AND A THREE-DIMENSIONAL BIOCOMPATIBLE AND BIODEGRADABLE MATRIX CONSISTING OF A HYALURONIC ACID DERIVATIVE		
<b>(57) Abstract</b>  A biologic material comprising the following two components: a) an efficient culture of autologous or homologous bone marrow stem cells partially or completely differentiated into connective tissue specific cells further comprising the extracellular matrix secreted by said connective tissue cells, or alternatively: a') the extracellular matrix secreted by: bone marrow stem cells partially or completely differentiated into a specific connective tissue, or alternatively, the specific homologous mature connective tissue cells, said extracellular matrix being free from any cellular component, and b) a three-dimensional biocompatible and biodegradable matrix consisting of a hyaluronic acid derivative. The processes for preparing said biologic material and the use thereof in tissue grafts.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

A BIOLOGIC MATERIAL COMPRISING AN EFFICIENT CULTURE OF BONE MARROW  
STEM CELLS PARTIALLY OR COMPLETELY DIFFERENTIATED INTO CONNECTIVE  
TISSUE CELLS AND A THREE DIMENSIONAL BIOCOMPATIBLE AND BIODEGRADABLE  
MATRIX CONSISTING OF A HYALURONIC ACID DERIVATIVE

## 5 FIELD OF THE INVENTION

The present invention relates to a biologic material, a process for  
its preparation and the use thereof in tissue grafts.

## BACKGROUND OF THE INVENTION

The loss of cutaneous material due to various causes, traumatic or  
10 metabolic for example, can sometimes prove to be very slow-healing.  
This can be due to metabolic or local circulatory causes, the  
patient's poor state of health or to the size of the wound, as in the  
case of extensive burns. The ineffectiveness of pharmacological  
therapy has led physicians to resort to reconstructive surgery, using  
15 skin grafts from the same patient whenever possible. An important  
breakthrough in the treatment of such lesions is the use of techniques  
for *in vitro* cell culture.

Another problem involved in the preparation of skin substitutes is  
represented by the supply of fibroblasts to seed onto the  
20 biocompatible matrices. Indeed, it is not always easy to isolate  
fibroblasts from dermal tissues, especially in the case of elderly or  
severely weakened subjects. One solution to this problem is offered by  
the mesenchymal cells present in bone marrow tissue. These cells are  
very active and can be suitably differentiated into various cell lines  
25 when placed in the correct conditions. From these stem cells it is  
possible to obtain differentiated cells such as fibroblasts,

- 2 -

adipocytes, myoblasts, osteoblasts, chondrocytes.

J. Rheinwald and H. Green (Cell, 6, 1975, 331-344) were the first to cultivate keratinocytes which could be successfully used to cover skin lesions in clinical practice (G. G. Gallico et al., N. Engl. J. Med., 5 311, (1984), 448-451). This innovative technique proved to have its limits, however, the most serious being the extreme fragility of the epithelial layer and the very low take rate. To overcome these limitations, dermal derivatives have been constructed on which keratinocytes can be grown. Yannas et al. (Science, 215, (1982), 174-10 176) used a mixture of collagen and glycosaminoglycans to obtain a reabsorbable porous material to serve as a skin substitute on lesions characterised by the loss of cutaneous substance.

S. Boyce and J. Hansbrough (Surgery, 103 (1988), 421-431) described the use of layers of collagen and glycosaminoglycans as supports on 15 which to grow keratinocytes for subsequent graft.

Another system for the preparation of dermal substitutes is represented by fibroblast cultures on biocompatible three-dimensional matrices based on synthetic or semisynthetic polymers. It is possible to seed and grow fibroblasts on these structures, thus enabling the 20 production of an extracellular matrix similar to that of natural connective tissue.

Some well-known examples of dermal substitutes are:

- 1) Dermagraft, developed by Advanced Tissue Science (California), in which human fibroblasts are seeded and cultivated on a matrix formed 25 by polylactic, polyglycolic or polygalactoside acid. These fibroblast-populated matrices are subsequently seeded with keratinocytes, to enhance their more "physiological" growth;

- 3 -

- 2) Graft-skin, by Organogenesis Inc. (Boston U.S.A.) composed of a collagen substrate on which heterologous human fibroblasts are seeded;
- 3) AlloDerm, produced by Life Cell Corp. (Texas, U.S.A.), constituted by human or pig dermis, left intact and stored at a low temperature.
- 5 Before use, it can be seeded with autologous fibroblasts and keratinocytes and then used for grafting.

Although these products represent good biological supports for *in vitro* cultures, their *in vivo* application is somewhat limited, due to immunological reactions against their non-autologous protein

10 components, as well as to the risk of viral contamination.

Lastly, other products deriving from hyaluronic acid are known to be used in skin grafts thanks to their highly biocompatible and biodegradable materials (Benedetti et al., Biomaterials, 14 (1993) 1154-1160; Cortivo R. et al., Biomaterials, 12 (1991) 727-730) and

15 their lack of immunoreactivity. Indeed, as hyaluronic acid is a component of the extracellular matrix it releases completely natural fragments during its degradation in the tissues.

#### SUMMARY OF THE INVENTION

The present invention relates to a biologic material comprising the

20 following two components:

- a) an efficient culture of autologous or homologous bone marrow stem cells partially or completely differentiated into cellular lines of a specific connective tissue and further comprising the extracellular matrix produced by said connective tissue cells,
- 25 or alternatively
- a') the extracellular matrix secreted by:
- bone marrow stem cells partially or completely differentiated into a

- 4 -

specific connective tissue, or alternatively,

- the specific homologous mature connective tissue cells,  
said extracellular matrix being free from any cellular component,  
and

- 5 b) a three - dimensional biocompatible and biodegradable matrix  
consisting of a hyaluronic acid derivative.

The present invention further relates to the processes for preparing  
said biologic material.

When the biologic material according to the present invention contains  
10 the component (a) or the component (a') being the extracellular  
matrix secreted by connective tissue cells coming from partial or  
complete differentiation of bone marrow stem cells, the process  
comprises the following steps:

i) isolating said homologous or autologous stem cells from the bone  
15 marrow.

ii) transferring said isolated stem cells onto said biocompatible  
three-dimensional matrix consisting of a hyaluronic acid ester, and

iii) growing and developing said stem cells upon and inside the  
biomaterials, by dipping the biologic material coming from the  
20 preceding step in a culture medium containing also a differentiating  
factor in case the desired connective tissue cells are different from  
fibroblasts, thereby obtaining the biologic material containing the  
component (a),

and optionally

25 iv) removing the homologous cellular component of (a), by osmotic  
lysis, thereby obtaining the biologic material containing the above  
mentioned component (a').

- 5 -

The process for preparing the biologic material according to the present invention containing the component (a') secreted by mature specific connective tissue cells comprises the following steps:

- (i') isolating said mature cells from the specific connective tissue, and growing them under conventional and specific growth condition depending on the specific mature connective cells
- (ii') transferring said mature connective tissue cells onto said three dimensional matrix consisting of said hyaluronic acid derivative,
- iii') growing and developing said connective tissue cells upon and inside said three dimensional matrix,
- iv') removing by means of osmotic lysis the cellular components.

The present invention further relates to the use of said biologic material in tissue grafts.

#### BRIEF DESCRIPTION OF THE FIGURES

- Figure 1: represents the immunohistochemical marking of Collagen I with monoclonal antibodies (avidin/biotin.; 200x) of:
- A: HYAFF<sup>R</sup> 11 non woven tissue in which human fibroblasts from bone marrow mesenchyma have been seeded. After 2 weeks culture the presence of type I collagen can be observed.
  - B: HYAFF<sup>R</sup> 11 containing human fibroblasts of dermal origin . In this case too, there is a definite positivity for collagen I.

Figure 2 : represents the immunohistochemical marking of collagen III with monoclonal antibodies (avidin /biotin; 200x) of:

- A: HYAFF<sup>R</sup>-11 with bone marrow mesenchymal fibroblasts 2 weeks after seeding, there is marked positivity to the reaction.
- B: HYAFF<sup>R</sup>-11 with fibroblasts of dermal origin 2 weeks after seeding, there is marked positivity to the reaction.

- 6 -

Figures 3: represent the immunoreaction with anticollagen IV antibodies (avidin/biotin; 100x) of:

A: HYAFF<sup>R</sup>-11 with bone marrow mesenchymal fibroblasts 2 weeks after seeding

5 B: HYAFF<sup>R</sup>-11 with dermal fibroblasts after 2 weeks in culture

The two different types of fibroblasts express collagen IV synthesis in the same manner.

Figure 4: represents immunohistochemical marking of fibronectin with monoclonal antibodies (avidin/biotin 100x) of:

10 A: HYAFF<sup>R</sup>-11 with fibroblasts from bone marrow 2 weeks after seeding

B: HYAFF<sup>R</sup>-11 with fibroblasts of dermal origin after 2 weeks in culture

Positivity to immunoreaction is marked in both types of fibroblast.

Figure 5: Immunohistochemical marking of laminin with monoclonal  
15 antibodies (avidin/ biotin; 200x)

A: HYAFF<sup>R</sup>-11 with fibroblasts from bone marrow 2 weeks after seeding.

B: HYAFF<sup>R</sup>-11 with dermal fibroblasts 2 weeks after seeding

The presence of laminin is very clear in both types of cultures.

#### DETAILED DESCRIPTION OF THE INVENTION

20 Preferably the hyaluronic acid derivative forming the three dimensional matrix of the biologic material according to the present invention is a hyaluronic acid ester like those disclosed in U.S. patent No. 4,851,521, which we incorporate by reference.

More preferably the hyaluronic acid ester is the benzyl ester having a  
21 degree of esterification varying from 25 to 100%.

According to a particular preferred embodiment hyaluronic acid benzylesters are used whose degree of esterification is respectively



- 7 -

75% (HYAFF<sup>R</sup>-11p75) and 100% (HYAFF<sup>R</sup>11).

The three- dimensional matrix consisting of a hyaluronic acid derivative are preferably in the form of non woven tissue, sponges, granules microspheres guide channels and gauzes.

- 5 According to a particularly preferred embodiment the three-dimensional biocompatible matrix of the biologic material according to the present invention are preferably in the form of a non woven-tissue.

The preparation of said non woven tissue consisting of a hyaluronic acid derivative and in particular of the ester of hyaluronic acid  
10 esters is disclosed in USP 5,520,916, which we incorporate herewith by reference.

The specific connective tissue cells, coming from the complete or partial differentiation of bone marrow stem cells contained in (a),  
in the biologic material according to the present invention, are  
15 preferably selected from the group consisting of fibroblasts, osteoblasts, myoblasts, adipocytes, chondrocytes and endothelial cells.

Therefore, when (a) comprises chondrocytes, being able able to form a cartilage tissue, the biologic material according to the present  
20 invention can be used for covering areas of eroded or degenerated cartilage.

When (a) comprises osteoblasts , being able to form a bone tissue, the biologic material according to the present invention can be used in case of loss of bone substance.

- 25 When (a) comprises fibroblasts, the biologic material of the present invention is grafted onto the damaged skin, (b) is absorbed within a given length of time thanks to its biodegradability, thus leaving

- 8 -

newly-formed dermal tissue at the site.

When autologous connective tissue cells have been seeded on the matrix consisting of the hyaluronic acid derivative, they can remain in the newlyformed connective tissue and contribute towards wound repair by  
5 means of the various growth factors and extra cellular matrix they secrete.

In case connective tissue coming from partial or complete differentiation of homologous bone marrow stem cells or homologous mature connective tissue are only available, the Applicant has found  
10 that with the biologic material containing the component (a') in place of component (a), it is possible to avoid undesired immunological reaction.

Therefore according to a preferred embodiment the connective tissue cells producing the extracellular matrix in this biologic material  
15 may derive from homologous partially or completely differentiated stem cells of bone marrow or from homologous mature connective tissue. The homologous mature connective tissue cells secreting component (a') are selected from the group consisting of fibroblasts, osteoblasts, myoblasts, adipocytes, chondrocytes and endothelial cells.

20 Mature fibroblasts may be isolated by dermal tissue coming either from autopsy or from biopsy, mature chondrocytes from autopsy cartilage, mature osteoblasts coming from biopsy fragments of bone tissue, mature muscular cells from biopsy fragments of muscular tissue, mature endothelial cells from biopsy fragments of small vasa or from dermis  
25 itself, mature adipocytes from biopsy fragments of adipous tissue.

Therefore the biologic material according to the present invention containing the component (a') can be used for the same purposes as

- 9 -

those contemplated for the biologic material containing the component (a).

In particular the biologic material according to the present invention both in the case it comprises (a), containing fibroblasts coming  
5 from partial or complete differentiation of bone marrow stem cells and in the case it contains (a'), secreted either by homologous or mature fibroblasts or by fibroblasts deriving from homologous partially or completely differentiated stem cells, can serve as a substrate for the *in vitro* seeding of autologous or homologous  
10 keratinocytes for subsequent graft.

This biologic materials is suitable for use as a dermal substitute in cutaneous lesions where substance has been lost .

In the process for respectively preparing the biologic materials containing the component (a) or alternatively the component (a'),  
15 secreted by homologous connective tissue cells obtained by partial or complete differentiation of bone marrow stem cells, step (i) preferably comprises the following operating conditions:

- 1) aspirating the bone marrow from the iliac crest or head of the femur ;
- 20 2) treating the liquid coming from step (1) in the presence of Hank's saline solution at +4°C and centrifuging the mixture thus obtained,
- 3) removing by aspiration the supernatant and the lipid layer,
- 4) removing erythrocytes in excess by using Percoll or Ficoll gradients, thereby obtaining the mesenchymal cells fraction,
- 25 5) centrifuging the mesenchymal fraction and recovering the solid;
- 6) resuspending the solid in a culture medium containing  $\alpha$ -MEM supplemented with 10% foetal calf serum, 1% L-glutamine 200mM, 1%

- 10 -

penicillin/streptomycin 10.000U/ 10.000 µg/ml;

7) seeding in a Petri dish at a density of  $50-100 \times 10^6$  nucleate cells/dish;

8) incubating the cells in the medium for 72 hours and changing the  
5 medium to remove the non adhered cells.

Step (ii) in said process is preferably carried out according to the following operating conditions:

1') detaching the cells of the colonies formed from said dishes, by using conventional methods such as trypsinisation.

10 2') depositing said cells at a density preferably comprised between  $1 \times 10^4$ -  $5 \times 10^4$  cells/cm<sup>2</sup> onto new culture Petri dishes, already containing a number of pieces of the three dimensional matrix consisting of a derivative of hyaluronic acid, these pieces of hyaluronic acid derivative adhering to the culture dishes by the  
15 addition of human plasma fibrin at the interface hyaluronic acid derivative- Petri dishes.

The medium utilized in step (iii) is chosen in function of the type of differentiation bone marrow stem cells are to be subjected to.

For example when stem cells are to be partially or completely  
20 differentiated into fibroblasts, said medium does not contain any differentiating factor, but preferably a fibroblasts growth factor such as bFGF (basic Fibroblast Growth Factor).

In this case a partial differentiation already occurs before stem cells are transferred onto the three dimensional matrix.

25 When stem cells are to be partially or completely differentiated into chondrocytes, this medium preferably contains  $\alpha$ -MEM supplemented with 10% foetal calf serum, 1% L-glutamin 200 mM, 1% penicillin -

- 11 -

streptomycin 10,000 U/10,000 µg/ml. 50 µg/ml/day ascorbic acid, 100-1000 nM dexamethasone. This medium is preferably changed twice a week. Alternatively the medium contains Ham's F12 supplemented with 10% foetal calf serum, 1% L-glutamin 200mM. 1% penicyllin/streptomycin  
5 10,000 U/10,000 µg/ml/day, 50 µg/ml/day ascorbic acid, 2% ethanol.

When stem cells are to be partially or completely differentiated into osteoblasts step (ii) namely the transfer of stem cells onto the three dimensional matrix occurs on said matrix previously treated with water containing hydroxy-apatite.

10 The medium in this case contemplated for step (iii) is α-MEM supplemented with 10% foetal calf serum, 1% L glutamin 200 mM, 1% penicyllin -streptomycin 10,000 U/10,000 µg/ml, 50 µg/ml/day ascorbic acid, 10-100 nM dexamethasone.

The step (iv), namely the osmotic lysis, for obtaining the component  
15 (a') is preferably carried out by using a solution of 5% deoxycholate.

Also in the process for preparing the biologic material containing the the component (a') secreted by mature connective tissue cells, step (iv') namely the osmotic lysis is preferably carried out by using the aforementioned dexycholate solution. The biologic material according

20 to the present invention can be cryopreserved so that a tissue bank can be built up to supply graft materials, or supports for keratynocytes cultures.

As a consequence of that each of the aforesaid processes for preparing the above mentioned biologic materials further comprise the  
25 final step consisting of cryopreserving according to conventional manner the obtained biologic material.

For purely indicative purposes, we present hereafter a few examples of

- 12 -

the characterization of newly-formed tissue.

EXAMPLE 1 *Isolation and culture of stem cells*

About 5-10 ml of bone marrow is aspirated from the iliac crest or head of femur.

- 5 The liquid, which also contains stromal bone fragments is placed in a 50 ml sterile tube and supplemented with 20-25 ml of Hank's saline solution at 4°C. The tube is centrifuged at approximately 1000 rpm for 5 minutes to eliminate the supernatant and the lipid layer, which are then aspirated. The excess of erythrocytes is eliminated by using
- 10 Percoll or Ficoll type gradients, after which the fraction containing mesenchymal cells is removed and centrifuged at 1000 rpm for 5 minutes. The pellet is resuspended removed and centrifuged in 5 ml culture medium ( $\alpha$ -MEM supplemented with foetal calf serum, 1% L-glutamine 200mM, 1% penicillin/ streptomycin 10,000 U/ 10,000  $\mu$ g/ml)
- 15 and seeded in Petri dishes with a diameter of 100 mm at a density of 50-100  $\times 10^6$  nucleate cells/dish.

EXAMPLE 2 *Transfer of stem cells in a three dimensional matrix consisting of HYAFF<sup>R</sup> 11 and HYAFF11 P75 and differentiation of stem cells into fibroblasts*

- 20 The cells are then left to incubate (37°C, pCO<sub>2</sub> about 5%) for 72 hours, after which the medium is changed in order to remove any non adhered cells. The mesenchymal cells remaining on the dish can be amplified by further passages (generally split ratio 1:3) and transferred to a non woven tissue matrices of HYAFF<sup>R</sup>-11 and HYAFF<sup>R</sup>
- 25 11p75, adding growth factor bFGF (1ng/ml) to the culture medium. Some time later (1-2 weeks) the cells inside the biomaterial take on a fibroblast appearance and express phenotype typical of fibroblasts

- 13 -

with the production of typical molecules of the connective matrix (collagen type I, II, III, IV, fibronectin, laminin).

EXAMPLE 3 Preparation of:

dermis  $\alpha$  containing:

- 5       - fibroblasts from bone marrow stem cells
- three dimensional matrix consisting of nonwoven HYAFF<sup>R</sup> 11

dermis  $\alpha'$  (control) containing:

- fibroblasts coming from human dermis
- three dimensional matrix consisting of nonwoven HYAFF<sup>R</sup> 11

10   dermis  $\beta$  containing:

- fibroblasts from bone marrow stem cells
- three dimensional matrix consisting of nonwoven HYAFF<sup>R</sup> 11 p75

dermis  $\beta'$  (control) containing:

- fibroblasts coming from human dermis
- 15   - three dimensional matrix consisting of nonwoven HYAFF<sup>R</sup> 11 p75

Pieces of tissue (1.5X 1.5 cm) comprised of both HYAFF<sup>R</sup> 11p75 and HYAFF<sup>R</sup> 11, are separately attached onto culture dishes by means of a fibrin clot. Human fibroblasts obtained from skin explants or from mesenchymal stem cells from bone marrow isolated and grown as  
20 described in Example 1 are separately seeded on the biomaterial at a density of  $10^4$  cells x cm<sup>2</sup> in 0.2 ml of medium, soaking the biomaterial slowly. After about 30 minutes, DMEM culture medium complete with 10% FCS and 50 µg/ml of l-ascorbic acid are added and the dishes are incubated at 37°C.

- 25   The medium is changed every 48 hours and the cultures are observed by phase-contrast microscope.

The pieces of biomaterial made of HYAFF<sup>R</sup> 11p75 can be cultured only

- 14 -

for 7 days and since it has been seen that, in the case of fibroblast cultures on HYAFF-11p75, the biomaterial begins to dissolve in the medium after 7 days. HYAFF-11, on the other hand, can be kept in culture for much longer (about 6 weeks). In this case, the pieces  
5 of HYAFF-11 are incubated with the cells for periods of 7, 14 and 21 days.

At the end of the culture period, the matrices of hyaluronic acid benzylester HYAFF<sup>R</sup> 11 p75 and HYAFF<sup>R</sup> 11, containing the fibroblasts from stem cells and the corresponding ones containing  
10 fibroblasts from human skin are detached from the dish without using lithic enzymes and divided into two parts.

One is fixed in formalin for routine histological tests and the other is frozen in liquid nitrogen and stored for  
subsequent immunohistochemical investigation.

15 The pieces fixed in formalin are stained with hematoxylin/eosine or by van Gieson's method, while the frozen material is stained immunohistochemically with mono- or polyclonal antibodies to show the presence of: fibronectin, collagen I, II and IV, laminin.

#### Results of histological staining

##### 20 Hematoxylin/eosin

Elongated cells with typical fibroblast morphology are observed both in HYAFF<sup>R</sup> 11p75 and HYAFF<sup>R</sup> 11 biomaterials. From a morphological point of view, the fibroblasts obtained from dermis and those obtained from bone marrow mesenchymal cells are similar in appearance. In the case  
25 of HYAFF<sup>R</sup> 11, the fibres of the biomaterial are well preserved, while the HYAFF<sup>R</sup> 11p75 fibres show signs of disintegration.

Analysis of the biomaterial shows the presence of a delicate mesh of



- 15 -

fine fibrils which turn pale pinkish red on staining with the Van Gieson method, confirming that they are collagen fibrils neosynthesized by the fibroblasts.

Immunohistochemical characterization

5 The following antibodies were used to reveal the most representative molecules in the extracellular matrix:

- 1) human I anticollagen monoclonal antibodies
- 2) human III anticollagen monoclonal antibodies
- 3) human IV anticollagen monoclonal antibodies
- 10 4) human antifibronectin monoclonal antibodies
- 5) human antilaminin monoclonal antibodies

The extracellular matrix deposited by the fibroblasts, both of dermal and bone marrow mesenchymal derivation, proved to be positive to the above immunoreactions. In particular, a notable fibrillar collagen (I  
15 and III) component was observed, as well as collagen IV. The typical adhesive molecules, fibronectin and laminin, which are characteristic of dermal tissue, are clearly expressed by these fibroblast cells, showing that a complete extracellular scaffold can be constituted within the matrices used by the Applicant.

20 EXAMPLE 4: Cryopreservation of dermis  $\alpha$  and dermis  $\beta$  prepared as described in Example 3

In order to demonstrate the possibility of preserving the artificial dermis obtained from stem cell culture in cold storage, the pieces of biomaterial containing the cells were frozen in the presence of a cold  
25 storage agent (dimethylsulfoxide, DMSO). The cultures were removed and placed in capsules containing DMEM, FCS and 10% DMSO, cooled to 4°C and then frozen to -80°C 5 minutes later.

- 16 -

One week later, the pieces of HYAFF<sup>R</sup> 11p75 are thawed from frozen and rapidly heated to 37°C, washed several times with DMEM with 10% FCS in order to eliminate the DMSO. They are left in an incubator for 24 hours, after which the cultures are transferred onto new pieces of  
5 HYAFF<sup>R</sup> 11p75 biomaterial of the same dimensions, which had been attached to culture dishes. This step is necessary to provide the cells with a new support, as the original nonwoven tissue starts to dissolve in the medium after 7 days.

The pieces of HYAFF<sup>R</sup> 11, on the other hand, are reused for culture  
10 after freezing in the conditions described above. All the thawed biomaterials are cultured for 7 days and then analysed as described in example 1. These new findings are similar to those described in example 1 and the tests performed with trypan blue staining show that the cells present in the HYAFF<sup>R</sup> 11 matrix are still viable after  
15 thawing.

Figures 1-5/A-B show histological photographs of the HYAFF<sup>R</sup> 11 nonwoven biomaterial wherein human fibroblasts from bone marrow and dermis have been seeded. Each figure describes the relative immunolocalization of collagen I, III, IV, fibronectin and laminin.  
20 The various biomaterials made of HYAFF<sup>R</sup> 11 and HYAFF<sup>R</sup> 11p75 (gauzes, sponges, membranes) do not differ in any substantial way one from the other as far as fibroblast growth and the deposit of extracellular matrix is concerned.

EXAMPLE 5: *biological material coming from the lysis of the cellular*  
25 *component of dermis  $\alpha$ ,  $\alpha'$ ,  $\beta$  and  $\beta'$*

The possibility of obtaining matrices of artificial dermis *in vitro* by the above-described method, with subsequent removal of the cellular

- 17 -

component, was assessed as follows:

After the culture process described in Examples 1 and 2, the pieces of HYAFF<sup>R</sup> biomaterial are treated with distilled water and then with 5% sodium deoxycholate to lyse the fibroblasts present. These two  
5 treatments lead to cellular lysis and solubilization of the membranes, leaving the extracellular component more or less intact. Subsequent to this treatment, the histological and immunohistological examination of the pieces of biomaterial is performed as described in the previous examples.

10 Staining of the extracellular matrix with the specific antibodies shows that the procedure of elimination of the cellular component does not alter the architecture or composition of the extracellular matrix, which appears similar, in all respects to that of the starting matrix, before cells removal.

15 EXAMPLE 6 *Conditions for the promotion of stem cell differentiation towards chondrogenesis*

Stem cells, isolated as described in Example 1, are placed on matrices of non woven HYAFF<sup>R</sup> 11 and grown in a culture medium with a special composition:  $\alpha$ -MEM supplemented with 10% foetal calf serum, 1% L-  
20 glutamin 200mM, 1% penicillin /streptomycin 10,000U/10,000  $\mu$ g/ml, 50  $\mu$ g/ml/day ascorbic acid , 100-1000nM dexamethasone. The cells are seeded at high concentrations( mass culture technique): at a mean density of  $5 \cdot 10^4$  cells/cm<sup>2</sup>. The culture medium is normally changed  
25 twice a week. Alternatively, the following medium can be used: Ham's F12 supplemented with foetal calf serum, 1% L-glutamin 200mM, 1% penicillin/streptomycin 10,000U/10,000  $\mu$ g/ml. 50 $\mu$ g/ml/day ascorbic acid, 2% ethanol.

- 18 -

Suitable phenotypic (chondrocyte) expression is monitored as follows:

- morphological observation with an optical microscope;
- specific staining of histological specimens with Alcian blue , toluidine blue and type II anti-collagen monoclonal antibodies;
- 5 - quantifications of the supernatant for the production of glycosaminoglycans and type II collagen.

In both the culture medium supplemented with dexamethasone and in that containing 2% ethanol, a high percentage of differentiation of the stem cells towards chondrocytes can be observed.

10 EXAMPLE 7: Conditions for the promotion of stem cell differentiation towards osteogenesis

In order to promote differentiation towards osteogenesis mesenchymal cells are grown on non-woven HYAFF<sup>R</sup> 11 with the following culture medium:  $\alpha$ -MEM supplemented with 10% foetal calf serum, 1% L-glutamin  
15 200mM, 1% penicillin /streptomycin 10,000U/10,000  $\mu$ g/ml, 50  $\mu$ g/ml/day ascorbic acid , 10-100 nM dexamethasone.

Before seeding, the HYAFF<sup>R</sup> 11 material is treated for 12-24 hours with water containing hydroxy-apatite. The culture medium is normally changed twice a week.

20 Suitable phenotypic (osteocyte) expression is monitored by:

- morphological observation with an optical microscope;
- specific staining of histological specimens according to Von Kossa;
- histochemical staining to reveal the presence alkaline  
25 phsosphatase activity.

In these experimental conditions it is possible to observe how the presence of hydroxy-apatite crystals in the HYAFF<sup>R</sup> 11 induces the

- 19 -

mesenchymal cells towards osteocytes.

- 20 -

# CLAIMS

1. A biologic material comprising the following two components:
  - a) an efficient culture of autologous or homologous bone marrow stem cells partially or completely differentiated into cellular lines of a specific connective tissue and the extracellular matrix produced by  
5 said connective tissue cells,  
or alternatively  
a') the extracellular matrix secreted by:
    - said bone marrow stem cells partially or completely differentiated into specific connective tissue cells, or  
10 - the specific mature connective tissue cells,  
said extracellular matrix being free from any cellular component,  
and  
b) a three -dimensional biocompatible and biodegradable matrix consisting of a hyaluronic acid derivative.
- 15 2. The biologic material according to claim 1 wherein the component (b) is in the form of a non woven tissue, sponges, granules, microspheres, guide channels and gauzes.
3. The biologic material according to claim 2 wherein the component  
20 (b) is in the form of a non woven tissue.
4. The biologic material according to anyone of claims 1 - 3 wherein said hyaluronic acid derivative is a hyaluronic acid ester having a degree of esterification comprised between 25 and 100%.
5. The biologic material according to claim 4 wherein the hyaluronic  
25 acid benzylesters are used having respectively a degree of esterification of 75% or 100%.
6. The biologic material according to anyone of claims 1-5, wherein

- 21 -

said extracellular matrix of (a') is secreted by a homologous cellular culture.

7. The biologic material according to anyone of claims 1-6 wherein said bone marrow stem cells are partially or completely differentiated  
5 into specific connective tissue cells selected from the group consisting of: fibroblasts, osteoblasts, myoblasts, adipocytes, chondrocytes and endothelial cells.

8. The biologic material according to claim 7, wherein said bone marrow stem cells, are partially or completely differentiated into  
10 chondrocytes, for use in covering areas of eroded or degenerated cartilage.

9. The biologic material according to claim 7, wherein said stem cells are partially or completely differentiated into osteoblasts, for use in case of loss of bone substance.

15 10. The biologic material according to claim 7, wherein said bone marrow stem cells are partially or completely differentiated into fibroblasts for use as a substrate for the *in vitro* seeding of autologous or homologous keratinocytes for subsequent graft.

11. The biologic material according to claim 7, wherein said bone  
20 marrow stem cells are partially or completely differentiated into fibroblasts for use as a dermal substitute to dress skin lesion.

12. The biologic material according to anyone of claims 1-6 wherein said mature connective tissue cells secreting the extracellular matrix (a') are selected from the group consisting of: fibroblasts,  
25 osteoblasts, myoblasts, adipocytes, chondrocytes and endothelial cells.

13. The biologic material according to claim 12 wherein the component

- 22 -

(a') is secreted by chondrocytes for use in covering areas of eroded or degenerated cartilage.

14. The biologic material according to claim 12 wherein the component (a') is secreted by osteoblasts, for use in case of loss of bone substance.

15. The biologic material according to claim 12 wherein the component (a') is secreted by fibroblasts for use as a substrate for the *in vitro* seeding of autologous or homologous keratinocytes for subsequent graft.

16. The biologic material according to claim 12 wherein the component (a') is secreted by fibroblasts for use as dermal substitute to dress skin lesion.

17. A process for preparing the biologic material according to anyone of claims 1-11 containing the component (a) or the component (a'), which is secreted by connective tissue cells obtained by partial or complete differentiation of bone marrow stem cells, comprising the following steps:

- i) isolating said homologous or autologous stem cells from the bone marrow,
- ii) transferring said isolated stem cells onto said biocompatible three-dimensional matrix consisting of a hyaluronic acid ester, and
- iii) growing said stem cells upon and inside the biomaterials in a medium containing also a differentiating factor in case the desired connective tissue cells are different from fibroblasts, thereby
- obtaining the biologic material containing the component (a),
- iv) removing the cellular component of (a), by osmotic lysis thereby obtaining the biologic material containing the above mentioned



- 23 -

component (a').

18. The process according to claim 17 wherein step (i) comprises the following operating conditions:

- 1) aspirating the bone marrow from the iliac crest or head of the femur ;
- 2) treating the liquid coming from step (1) in the presence of Hank's saline solution at +4°C and centrifuging the mixture,
- 3) removing by aspiration the supernatant and the lipid layer,
- 4) removing erythrocytes in excess by using Percoll or Ficoll gradients, thereby obtaining the mesenchymal cells fraction,
- 5) centrifuging the mesenchymal cells fraction and recovering the solid;
- 6) resuspending the solid in 5 ml of culture medium ( $\alpha$ -MEM supplemented with 10% foetal calf serum, 1% L-glutamine 200mM, 1% penicillin/streptomycin;
- 7) seeding in a Petri dish at a density of  $50-100 \times 10^6$  nucleate cells/dish;
- 8) incubating the cells in the medium for 72 hours and changing the medium to remove the non adhered cells.

19. The process according to anyone of claims 17 and 18 wherein step (ii) is carried out according to the following operating conditions:

- 1') detaching the cells of the colonies formed from said dishes, by using conventional methods such as trypsinisation
- 2') depositing said cells at a density preferably comprised between  $1 \times 10^4 - 5 \times 10^4$  cells/cm<sup>2</sup> onto new culture Petri dishes, already containing a number of pieces of the three dimensional matrix consisting of a derivative of hyaluronic acid, these

- 24 -

pieces of hyaluronic acid derivative adhering to the culture dishes by the addition of human plasma fibrin at the interface hyaluronic acid derivative- Petri dishes.

20. The process according to anyone of claims 17-19 wherein the medium  
5 utilized in step (iii) is chosen in function of the type of differentiation bone marrow stem cells are subjected to.

21. The process according to claim 20 wherein when stem cells are to be partially or completely differentiated into fibroblasts, said medium does not contain any differentiating factor, but optionally  
10 fibroblasts growth factor.

22. The process according to claim 20 wherein when stem cells are to be partially or completely differentiated into chondrocytes, this medium contains  $\alpha$ -MEM supplemented with 10% foetal calf serum, 1% L-glutamin 200 mM, 1% penicillin -streptomycin 10,000 U/10,000  $\mu$ g/ml,  
15 50  $\mu$ g/ml/day ascorbic acid, 100-1000 nM dexamethasone.

23. The process according to claim 20, wherein when stem cells are to be partially or completely differentiated into chondrocytes, this medium contains Ham's F12 supplemented with 10% foetal calf serum, 1% L-glutamin 200mM, 1% penicyllin/streptomycin 10,000 U/10,000  
20  $\mu$ g/ml/day, 50  $\mu$ g/ml ascorbic acid, 2% ethanol.

24. The process according to claim 20, wherein, when stem cells are to be partially or completely differentiated into osteoblasts step (ii) is carried out on said matrix previously treated with water containing hydroxy-apatite and the medium used in step (iii) contains:  
25  $\alpha$ -MEM supplemented with 10% foetal calf serum, 1% L glutamin 200 mM, 1% penicyllin -streptomycin 10,000 U/10,000  $\mu$ g/ml, 10-100 nM dexamethasone.

- 25 -

25. The process according to anyone of claims 17-24 wherein step (iv) is carried out by using a solution of 5% deoxycholate.
26. The process according to anyone of claims 17-25 further comprising the final step of cryopreserving the obtained biologic material.
- 5 27. A process for preparing the biologic material according to anyone of claims 1-6, and 11-16 comprising the following steps:
- (i') isolating said mature cells from the specific connective tissue, and growing them under conventional and specific growth condition depending on the specific mature connective cells
  - 10 (ii') transferring said mature connective tissue cells onto said three dimensional matrix consisting of a hyaluronic acid derivative,
  - iii') growing and developing said connective tissue cells upon and inside this three dimensional matrix,
  - iv') removing by means of osmotic lysis the cellular components.
- 15 28. The process according to claim 27 wherein step (iv') is carried out by using a solution of 5% deoxycholate.
29. The process according to anyone of claims 27 and 28 further comprising the final step of cryopreserving the obtained biologic material.




FIG. 1A



FIG. 1B



FIG. 2A



FIG. 2B




FIG. 3A




FIG. 3B




FIG. 4A



FIG. 4B

5/5



FIG. 5A



FIG. 5B



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 96/05093

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61L27/00 A61L15/28 C12N5/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 96 37519 A (FIDIA ADVANCED BIOPOLYMERS SRL ;BELLINI DAVIDE (IT); CALLEGARO LAN) 28 November 1996 see page 6, line 11 - line 19; claims ---	1,2
A	EP 0 462 426 A (FIDIA SPA) 27 December 1991 see claims; examples 1-3 ---	1-29
A	US 5 197 985 A (CAPLAN ARNOLD I ET AL) 30 March 1993 see claims; examples 1,2 ---	1-29
A	EP 0 265 116 A (FIDIA SPA) 27 April 1988 see examples ---	1
	--- -/-	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*Z\* document member of the same patent family

Date of the actual completion of the international search

19 March 1997

Date of mailing of the international search report

- 3 -04- 1997

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 631 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

ESPINOSA, M

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 96/05093

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 526 865 A (FIDIA SPA) 10 February 1993 see claims ---	1
A	WO 93 11803 A (M U R S T) 24 June 1993 see claims; examples & US 5 520 916 A cited in the application ---	1
A	BIOMATERIALS, vol. 12, no. 8, October 1991, GB, pages 727-730, XP002027830 R. CORTIVO, P. BRUN, G. ABATANGELO: "IN VITRO STUDIES ON BIOCOMPATIBILITY OF HYALURONIC ACID ESTERS" cited in the application see abstract -----	1

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 96/05093

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9637519 A	28-11-96	IT PD950101 A	22-11-96
		AU 6001296 A	11-12-96
EP 0462426 A	27-12-91	IT 1248934 B	11-02-95
		AU 637235 B	20-05-93
		AU 7806691 A	05-12-91
		CA 2043527 A	02-12-91
		JP 4231061 A	19-08-92
		US 5326356 A	05-07-94
US 5197985 A	30-03-93	NONE	
EP 0265116 A	27-04-88	AU 610087 B	16-05-91
		AU 7960087 A	21-04-88
		CA 1317287 A	04-05-93
		CN 1025035 B	15-06-94
		FI 96610 B	15-04-96
		JP 63105003 A	10-05-88
		NO 175374 B	27-06-94
		US 4957744 A	18-09-90
		ZA 8707559 A	13-04-88
EP 0526865 A	10-02-93	IT 1251151 B	04-05-95
		AU 654027 B	20-10-94
		AU 2084092 A	11-02-93
		CA 2075340 A	06-02-93
		JP 5255124 A	05-10-93
		US 5503848 A	02-04-96
WO 9311803 A	24-06-93	IT 1254704 B	09-10-95
		AU 669147 B	30-05-96
		AU 3346693 A	19-07-93
		BG 98863 A	31-05-95
		EP 0618817 A	12-10-94
		FI 942894 A	18-08-94
		HU 68680 A	28-07-95
		JP 7502430 T	16-03-95
		NO 942330 A	17-08-94
		US 5520916 A	28-05-96